共 85 条
[1]
Christou NV(1996)Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage Arch Surg. 131 1193-1201
[2]
Turgeon P(2007)Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intra-abdominal infections in Spain Scand J Infect Dis. 39 947-955
[3]
Wassef R(2010)Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America Clin Infect Dis. 50 133-164
[4]
Tellado JM(2010)Recommendations in the empiric anti-infective agents of intra-abdominal infection Cir Esp. 87 63-81
[5]
Sen SS(2007)Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination Expert Rev Anti Infect Ther. 5 365-383
[6]
Caloto MT(2003)Ertapenem versus piperacillin/tazobactam in the treatment of complicated intra-abdominal infections: results of a double-blind, randomized comparative phase III trial Ann Surg. 237 235-245
[7]
Solomkin JS(2010)Epidemiologic trends, occurrence of extended-spectrum beta-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: analysis of global trend data from 2002–2007 from the SMART study Surg Infect (Larchmt). 11 371-378
[8]
Mazuski JE(2011)Antimicrobial susceptibility of Gram-negative organisms from intra-abdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002–2010) Rev Esp Quimioter. 24 223-232
[9]
Bradley JS(2012)Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial Surg Infect (Larchmt). 13 102-109
[10]
Guirao X(2012)Excess deaths associated with tigecycline after approval based on non-inferiority trials Clin Infect Dis. 54 1699-1709